BCAL FPO logo

BCAL FPO (BDX)

Market Closed
CXA CXA
- Market Cap
- P/E Ratio
3.8% Div Yield
84,800 Volume
- Eps
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 26 days

Summary

BDX closed Thursday higher, an increase of 4.84% from Wednesday's close, completing a monthly decrease of -1.52%. Over the past 12 months, BDX stock lost -38.1%.
BDX pays dividends to its shareholders, with the most recent payment made on Jun 30, 2025. The next estimated payment will be in In 2 months on Sep 30, 2025 for a total of A$1.04.
The last earnings report, released on May 01, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.16%, based on the last three reports. The next scheduled earnings report is due on Jul 31, 2025.
BCAL FPO has completed 5 stock splits, with the recent split occurring on Apr 01, 2022.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
3 Undervalued Dividend King Stocks With Over 50% Upside Potential

3 Undervalued Dividend King Stocks With Over 50% Upside Potential

As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields.

247wallst | 3 days ago
Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (BDX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.

Seekingalpha | 3 weeks ago
Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson: A Dividend King Facing Challenges Offers Value

Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.

Seekingalpha | 3 weeks ago

BCAL FPO Dividends

Becton, Dickinson and Company logo
BDX In 2 months
Estimated
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 weeks ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 6 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 9 months ago
Paid
Quarterly
$0.95 Per Share
Becton, Dickinson and Company logo
BDX 10 Jun 2024
Paid
Quarterly
$0.95 Per Share

BCAL FPO Earnings

7 Aug 2025 (In 1 month) Date
3.42
Cons. EPS
-
EPS
31 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
2.99
Cons. EPS
3.43
EPS
7 Nov 2024 Date
3.77
Cons. EPS
3.81
EPS
Becton, Dickinson and Company logo
BDX In 2 months
Estimated
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 weeks ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 3 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 6 months ago
Paid
Quarterly
$1.04 Per Share
Becton, Dickinson and Company logo
BDX 9 months ago
Paid
Quarterly
$0.95 Per Share
Becton, Dickinson and Company logo
BDX 10 Jun 2024
Paid
Quarterly
$0.95 Per Share
7 Aug 2025 (In 1 month) Date
3.42
Cons. EPS
-
EPS
31 Jul 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
1 May 2025 Date
-
Cons. EPS
-
EPS
30 Jan 2025 Date
2.99
Cons. EPS
3.43
EPS
7 Nov 2024 Date
3.77
Cons. EPS
3.81
EPS

BCAL FPO (BDX) FAQ

On which exchange is it traded?

BCAL FPO is listed on NYSE.

What is its stock symbol?

The ticker symbol is BDX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.8%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Jul 31, 2025.

Has BCAL FPO ever had a stock split?

BCAL FPO had 5 splits and the recent split was on Apr 01, 2022.

BCAL FPO Profile

Medical - Instruments & Supplies Industry
Healthcare Sector
Thomas E. Polen Jr. CEO
CXA Exchange
US0758871091 ISIN
US Country
70,000 Employees
10 Mar 2025 Last Dividend
1 Apr 2022 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800